JENBURPH · Jenburkt Pharmaceuticals Ltd · Biotechnology & Drugs
JENBURPH · Jenburkt Pharmaceuticals Ltd · Biotechnology & Drugs
As of 06 Nov close
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 16 Oct 2026
Revenue (latest Q)
₹36 Cr
Revenue YoY
PAT YoY
-24.4%
Operating margin
Revenue, last 5 quarters
P/E (TTM)
P/B
2.1
P/S (TTM)
2.7
Sector P/E
33.6
Dividend yield
+2.3%
Source: Yahoo Finance, as of 29 Oct 2026
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| JENBURPH (this stock) | 11.7 | 2.1 | +19.5% | +16.7% | 0.01 | +2.3% |
| Sun Pharmaceutical Industries | 39.6 | 5.7 | +19.1% | +14.2% | 0.47 | +0.8% |
| Divi's Laboratories | 59.7 | 14.5 | +26.1% | +17.4% | 0 | +0.3% |
| Torrent Pharmaceuticals | 74.5 | 19.7 | +15.3% | +27.1% | 141.16 | +0.8% |
Promoter
stable
FII
falling 2q
MF
Not available from data source
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
No related news.
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
Governance disclosures
AI-generatedNo governance disclosures identified in JENBURPH's filed documents yet.